Abbott Reports Third-Quarter 2013 Results - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Abbott Reports Third-Quarter 2013 Results


Abbott’s third-quarter 2013 results show that worldwide reported sales increased 2%, including an unfavorable 2.3% effect of foreign exchange, the company announced in a press release. A sales disruption in Abbott’s International Nutrition business, caused by a supplier recall in early August 2013 in certain international markets of pediatric nutrition products, is estimated to have reduced Abbott's total worldwide sales growth by nearly 2%. Abbott confirmed its full-year 2013 ongoing EPS guidance range of $1.98–2.04.

The company’s Established Pharmaceuticals business segment sales increased 0.6% in the third quarter on an operational basis and decreased 2.9% on a reported basis, including an unfavorable 3.5% effect of foreign exchange. In key emerging markets, reported sales decreased 3.4%, including an unfavorable 5.7% effect of foreign exchange. Abbott is focused on implementing tailored strategies to drive accelerated growth across its key emerging markets. While recent macroeconomic and market pressures in certain emerging markets resulted in somewhat slower sales growth this quarter, growth rates in emerging markets have and are expected to continue to outpace the overall global economy and remain attractive over the long term, the company said in the press release. Other markets include developed markets, such as Western Europe and Japan, and other emerging markets globally. Sales in these geographies decreased 0.9% in the quarter on an operational basis and 2.4% on a reported basis, including an unfavorable 1.5% effect of foreign exchange.

Source: Abbott

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here